拨康视云-B 02592Stock Information

Stock Information · Old Rules
// Company Overview //
Stock Name拨康视云-B
Stock Code02592
Company Full Name拨康视云-B
Industry醫療保健
Principal Activities公司是一間以創新驅動的臨床階段眼科生物科技公司,致力于開發新型及差異化療法,致力于內部發現、開發及商業化同類首創及同類最佳眼科療法,以滿足全球未滿足的醫療需要。
Listing Date2025-07-03
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)8921 Research Drive Irvine, CA 92618 United States
Business Address (Hong Kong)No data
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websitehttps://www.cloudbreakpharma.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo
// Offering Information //
Offering Mechanism 机制B
Clawback Tiers机制B不设回拨,公开发售占比维持20.0%
Offer Period2025-06-24 to 2025-06-27
Offer PriceHK$ 10.10 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 5,050
Par ValueNo data
Global Offering Shares60,582,000
HK Public Offering Shares12,115,500 (20.0%)
International Placing Shares48,466,500 (80.0%)
Offer RatioNo data
Total Shares Post-IPONo data
Total Global Offering SizeHK$ 611,878,200
Public Offering SizeHK$ 122,366,550 (20.0%)
Oversubscription Multiple78.8x
Valid Applications29,007
Accepted Applications7,404
ReallocationNo
Total Funds RaisedHK$ 122,366,550
Greenshoe (Over-allotment Option)No
Final Public Offering Share20.0%
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 0
Pre-IPO Valuation (Last Round)No data
P/E Ratio-10.99
Profit/Loss StatusNo data
Period-End Cash BalanceNo data
Listing Expenses~HK$ 89,670,000
Listing Expenses / Funds RaisedNo data
Total Pre-IPO InvestmentNo data
// First Day Performance
First Day CloseLoading...
First Day OpenHK$ 9.5
First Day Change-38.61%
First Day Volume43953200.0
First Day Turnover318762000.0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約62.4%或325.9百萬港元將用于撥付核心產品CBT-001的持續臨床研發活動,以及注冊備案及獲批后研究所需資金; 2、約27.6%或144.1百萬港元將用于撥付持續臨床研發活動,包括研發人員及研發活動的成本及開支,以及核心產品CBT-009的注冊備案的所需資金; 3、約5.5%或28.7百萬港元將用于撥付生產設施及商業化活動所需資金; 4、約4.5%或23.5百萬港元將用作營運資金及其他一般企業用途。
// Underwriting Syndicate //
联席保荐人 (2)
建银国际金融有限公司 华泰金融控股(香港)有限公司
整体协调人 (4)
建银国际金融有限公司 华泰金融控股(香港)有限公司 招银国际融资有限公司 华富建业证券有限公司
联席账簿管理人 (19)
建银国际金融有限公司 华泰金融控股(香港)有限公司 中银国际亚洲有限公司 交银国际证券有限公司 中国银河国际证券(香港)有限公司 兴证国际融资有限公司 民银证券有限公司 招银国际融资有限公司 第一上海证券有限公司 复星国际证券有限公司 华福国际证券有限公司 工银国际证券有限公司 利弗莫尔证券有限公司 百惠证券有限公司 华富建业证券有限公司 瑞邦证券有限公司 善恒证券有限公司 浦银国际融资有限公司 盈立证券有限公司
联席牵头经办人 (19)
建银国际金融有限公司 华泰金融控股(香港)有限公司 中银国际亚洲有限公司 交银国际证券有限公司 中国银河国际证券(香港)有限公司 兴证国际融资有限公司 民银证券有限公司 招银国际融资有限公司 第一上海证券有限公司 复星国际证券有限公司 华福国际证券有限公司 工银国际证券有限公司 利弗莫尔证券有限公司 百惠证券有限公司 华富建业证券有限公司 瑞邦证券有限公司 善恒证券有限公司 浦银国际融资有限公司 盈立证券有限公司
// Cornerstone Investors // Allotment Results Announcement
#Investor NameShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 WaterLilyConsultantsInc. 157,992,705 18.83% 2026-07-02 2026-07-02
2 SKKETCHSHINELIMITED 49,634,271 5.92% 2026-01-02 2026-01-02
3 YicunHoldingsLimited 46,881,393 5.59% 2026-01-02 2026-01-02
4 GAOTEJIANEWCLOUD 37,225,703 4.44% 2026-01-02 2026-01-02
5 GrandDiamondLimited 26,789,367 3.19% 2026-01-02 2026-01-02
6 DesignTimeLimited 24,817,136 2.96% 2026-01-02 2026-01-02
7 上海德泓鑫商務諮詢合夥企業(有 24,817,136 2.96% 2026-01-02 2026-01-02
8 富策控股有限公司 15,544,000 25.66% 1.85%
9 海南倚鋒駿馬一期私募股權投資 11,454,063 1.37% 2026-01-02 2026-01-02
10 YunxinHoldingsLimited 8,873,587 1.06% 2026-01-02 2026-01-02
11 上海天壹睿曜企業管理合夥企業 8,272,379 0.99% 2026-01-02 2026-01-02
12 深圳市創東方長輝投資企業(有限 8,272,379 0.99% 2026-01-02 2026-01-02
13 ZhongyinHealthHoldings 8,036,810 0.96% 2026-01-02 2026-01-02
14 盈科值得普澤(平潭)股權投資合 5,809,857 0.69% 2026-01-02 2026-01-02
15 YunwenCapitalLimited 5,771,472 0.69% 2026-01-02 2026-01-02
16 IceTree,LLC 5,288,139 0.63% 2026-07-02 2026-07-02
17 江門市倚鋒駿馬二期創業投資合 5,090,694 0.61% 2026-01-02 2026-01-02
18 金華金開興證醫藥健康產業股權 4,467,085 0.53% 2026-01-02 2026-01-02
19 TheNiLegacyTrust 3,900,219 0.46% 2026-01-02 2026-01-02
20 上海屹玥企業管理合夥企業(有限 3,805,294 0.45% 2026-01-02 2026-01-02
21 IceTreeConsultants,Inc. 3,624,970 0.43% 2026-07-02 2026-07-02
22 TheLengLegacyTrust 1,344,009 0.16% 2026-01-02 2026-01-02
23 華泰資本投資有限公 231,500 0.38% 0.03%
// Directors & Management //
ChairmanNI Jinsong
Company Secretary歐子毅;馮雅芳
No director data available.
// Major Shareholders //
Major Shareholders & HoldingsWater Lily Consultants Inc.(26.36%);澳美制藥廠有限公司(11.38%)
// Allotment Benchmarks //
Pool A (Small Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
500 12,752 638 0.05
1,000 3,196 256 0.08
1,500 1,113 127 0.11
2,000 1,126 165 0.15
2,500 735 131 0.18
3,000 633 130 0.21
3,500 248 58 0.23
4,000 337 88 0.26
4,500 370 106 0.29
5,000 1,839 569 0.31
6,000 368 132 0.36
7,000 237 96 0.40
8,000 287 129 0.45
9,000 245 121 0.49
10,000 1,439 770 0.54
15,000 586 432 0.74
20,000 534 494 0.92
25,000 429 45 1.10
30,000 269 74 1.28
35,000 121 54 1.45
40,000 137 83 1.61
45,000 93 71 1.76
50,000 453 412 1.91
60,000 154 25 2.16
70,000 80 38 2.48
80,000 85 66 2.78
90,000 61 61 3.01
100,000 471 106 3.22
200,000 205 205 6.00
300,000 88 88 7.98
400,000 103 103 10.00
Pool B (Large Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
500,000 123 38 37.30
600,000 13 13 44.04
700,000 10 10 50.96
800,000 7 7 58.08
900,000 6 6 64.98
1,000,000 39 39 72.00
2,000,000 5 5 142.00
3,029,000 10 10 213.24
Offer Ratio
Allotment Benchmarks
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics